• President Trump signed an executive order mandating U.S. drug prices be set no higher than those in other developed nations, directly linking the policy to the 2025 midterm elections.
  • The administration sent warning letters to major pharmaceutical companies including Pfizer, AstraZeneca, and Johnson & Johnson, threatening federal intervention for non-compliance.
  • The 'most-favored-nation' pricing policy could significantly pressure pharmaceutical profits while potentially lowering costs for American consumers and taxpayers.

President Trump has escalated his administration's efforts to lower U.S. prescription drug costs, implementing aggressive new measures that tie pharmaceutical pricing directly to his party's midterm election strategy. The move represents one of the most significant federal interventions into drug pricing in decades.

On May 12, Trump signed an executive order requiring that U.S. drug prices, particularly for Medicaid patients, be capped at the "most-favored-nation" level—the lowest prices offered in other developed countries. The administration simultaneously dispatched letters to major pharmaceutical manufacturers warning that failure to comply would trigger further federal action.

"We are ending the free-riding by foreign nations that has burdened American patients for too long," a senior administration official told reporters on condition of anonymity. "The President has made clear this will be central to our midterm message."

The policy shift targets an industry where Americans currently pay roughly three times more for brand-name drugs compared to other developed countries. Despite representing less than 5% of the global population, the U.S. market accounts for approximately 75% of global pharmaceutical profits, creating what administration officials call an unsustainable imbalance.

Letters obtained from the administration show warnings sent to pharmaceutical giants including Pfizer, AstraZeneca, Johnson & Johnson, and others demanding they not offer any country better prices than what's available in the United States. The correspondence explicitly threatens using "all available government tools" to enforce compliance.

Industry response has been immediate and critical. "This approach threatens the very innovation that brings new medicines to patients," a spokesperson for a major pharmaceutical company said when reached for comment. "We're evaluating all options, including legal challenges."

The administration's push comes as drug pricing reform emerges as a central issue ahead of the 2025 midterms. Trump has framed high prescription costs as unacceptable while directly connecting administrative action to voter priorities, marking a significant shift toward aggressive negotiation in a sector historically dominated by market-driven pricing.

Previous administrations, including during Trump's first term, have attempted to curb drug prices with limited success. However, the most-favored-nation approach represents a substantial escalation in federal intervention, potentially creating ripple effects across global pharmaceutical markets.

Health policy experts remain divided on the potential outcomes. Some analysts project the policy could sharply reduce U.S. drug prices, particularly for expensive specialty medications, while others warn of unintended consequences including reduced drug availability and diminished research and development investment.

Efforts to reach several pharmaceutical companies for additional comment were unsuccessful. The White House declined to specify what additional enforcement measures might follow if companies resist compliance, though people familiar with the matter suggest everything from Medicaid reimbursement adjustments to importation policies remain under consideration.

Correction: An earlier version of this article misstated the percentage of global pharmaceutical profits attributed to the U.S. market. The correct figure is approximately 75%, not 80%.